The secret to enabling early cancer detection could be hidden in the microbiome, and, now, gut-testing startup Viome has the backing of the FDA to prove it.
J&J Vision extends cataracts land-grab with U.S., Canada approvals for vision-correcting intraocular lenses
Johnson & Johnson continued a string of recent approvals aimed at patients with cataracts, with the latest bringing its newer-generation intraocular lenses to U.S. and Canadian shores.
To help diagnose women with certain types of breast cancer, GE Healthcare is buying up a small French developer of a recently FDA-approved molecular imaging agent.
After nearly a century spent building out its portfolio of insulin pens and syringes, BD is finally ready to let its diabetes care business leave the nest.
Bluebird bio has disclosed the name of its oncology spinoff: 2seventy bio. The spinoff is taking cancer therapies and some executives, including the CEO and chief scientific officer, from bluebird.
Cancer vaccines that prime the immune system to recognize and eliminate cancer cells have gained traction lately. Scientists are pursuing a wide range of strategies including making vaccines from immune cells, tumor cells, tumor-associated proteins or their smaller components.
In a shift from traditional thinking that lumps together all cases of obesity, researchers are increasingly proving that a combination of genetic and environmental factors have resulted in several distinct forms of the condition, each requiring a different treatment.
While antibodies have drawn attention lately for fighting infectious diseases like COVID-19, AstraZeneca hopes to wield them against prostate cancer, and it’s starting with a proof-of-concept project with analytics startup Alchemab Therapeutics. The plan: to explore why some people get prostate cancer, but others don’t.
Cancer cells multiply out of control because they’re able to escape a mechanism known as programed cell death. But scientists at the Massachusetts Institute of Technology (MIT) and King’s College London have uncovered key functions of another pathway with a long evolutionary history that the body uses to dispose of those rogue cells.
To help patients better control their chronic pain and neuromodulation treatments from home, Medtronic is launching its first virtual, connected portal for spinal cord stimulation.